When the Senate Finance Committee held hearings in November 2004 to investigate whether the US Food and Drug Administration had ignored safety warnings about the painkiller Vioxx, David Ross was, by his own account, "furious." Not that he had any personal involvement with Vioxx; he was a scientist and midlevel manager overseeing other drug reviews at the agency. But he was furious that anyone would speak badly of the FDA—"my organization," as he called it—in public.
Advertisement
Survey Series
Institutions
For Advertisers
Morale Mire
FDA scientists are increasingly unhappy, due to in-house pressures and public criticism. How can the agency restore what it once was?
|
|||||||||
|
|||||||||
|
